Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Toujeo
| Field | Information |
|---|---|
| Medication Name | Toujeo |
| Generic Name | Insulin glargine (U-300) |
| Purpose | Long-acting insulin to improve glycemic control in adults with type 1 and type 2 diabetes mellitus. |
| Mechanism of Action | Insulin glargine is a long-acting basal insulin analog, with a prolonged duration of action due to a delayed absorption rate. It lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. |
| Dosage Forms | Solution for subcutaneous injection (SoloStar pen) |
| Available Strengths | 300 units/mL (U-300) |
| Dosage Frequency | Once daily, typically at the same time each day |
| Common Side Effects | Hypoglycemia (low blood sugar), injection site reactions (redness, swelling, itching), weight gain, edema |
| Serious Side Effects | Severe hypoglycemia, allergic reactions (rash, itching, swelling, difficulty breathing), hypokalemia (low potassium), heart failure |
| Drug Interactions | Other antidiabetic agents (oral and injectable), ACE inhibitors, ARBs, diuretics, MAOIs, salicylates, sulfonamide antibiotics, alcohol, corticosteroids, thyroid hormones, beta-blockers, sympathomimetic agents, thiazide diuretics |
| Important Notes | Monitor blood glucose regularly. Rotate injection sites to prevent lipodystrophy. Do not dilute or mix Toujeo with any other insulin. Consult a healthcare provider if you experience persistent side effects or have questions about your insulin regimen. |
| Storage | Unopened pens: Store in the refrigerator (36°F to 46°F [2°C to 8°C]). Do not freeze. Opened pens: Store at room temperature (below 86°F [30°C]) away from direct heat and light. Discard after 56 days, even if some insulin is left. |
| Missed Dose | Inject your dose as soon as you remember. Then, continue your regular schedule of injecting your insulin at the usual time each day. Do not take a double dose to make up for the forgotten dose. |
| Alternatives | Lantus (insulin glargine U-100), Basaglar (insulin glargine U-100), Tresiba (insulin degludec), Levemir (insulin detemir) |
Toujeo Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Lantus (insulin glargine U-100) | Long-acting insulin analog | Similar to Toujeo but at a different concentration (U-100). |
| Basaglar (insulin glargine U-100) | Long-acting insulin analog | A biosimilar of Lantus. Also U-100 concentration. |
| Tresiba (insulin degludec) | Ultra-long-acting insulin analog | Provides a more stable and prolonged insulin action compared to insulin glargine. |
| Levemir (insulin detemir) | Long-acting insulin analog | May require twice-daily dosing for some individuals. |
Toujeo Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Hypoglycemia (low blood sugar) | Severe Hypoglycemia (can lead to unconsciousness, seizures, or death) |
| Injection site reactions (redness, swelling, itching) | Allergic reactions (rash, itching, swelling, difficulty breathing) |
| Weight gain | Hypokalemia (low potassium) |
| Edema (swelling, especially in ankles and feet) | Heart failure (in patients at risk) |
Toujeo Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Type 1 Diabetes | Individualized; typically 1/3 to 1/2 of total daily insulin dose | Individualized; adjusted based on blood glucose monitoring | Administer subcutaneously once daily at the same time each day. Rotate injection sites. Never share your pen with others. |
| Type 2 Diabetes | Individualized; typically 0.2 units/kg once daily | Individualized; adjusted based on blood glucose monitoring | Administer subcutaneously once daily at the same time each day. Rotate injection sites. Never share your pen with others. |

